Waltham, MA, June 4, 2020 — Trinity Life Sciences, a leader in global life sciences solutions, finds that New Product Planning (NPP) pharmaceutical executives are uncertain about how COVID-19 will affect the volume of business development efforts. According to the new brief entitled Impact of COVID-19 on New Product Planning, NPP teams are mixed in their expectations for the volume of business development (BD) efforts to change in the near term due to the COVID-19 outbreak.
“NPP teams are seeking ways to overcome delays in clinical development and may be looking to BD as a way to fill that gap,” said Leslie Orne, Senior Partner and Chief Client Officer at Trinity. “Some respondents also thought depression of valuations and potential need for cash may create a climate of more deals in the wake of COVID-19, and NPP/BD groups should be ready to move quickly.”
The brief was based on a survey of NPP pharma leaders focusing on how they are approaching the challenges and uncertainty caused by COVID-19. The brief also finds that although NPP teams anticipate delays in market research as they shift to virtual methods, they may find healthcare providers’ availability to be better than they expect, enabling them to continue critical research and strategic decision-making in the near term.
For a full copy of Impact of COVID-19 on New Product Planning, please visit www.TrinityLifeSciences.com.
|For more information:|
Trinity Life Sciences
About Trinity Life Sciences
Trinity Life Sciences is a trusted strategic partner, providing evidence-based solutions for the life sciences. With over 20 years of experience, Trinity is committed to solving clients’ most challenging problems through exceptional levels of service, powerful tools, and data-driven insights. Trinity’s range of products and solutions includes industry-leading benchmarking solutions, powered by TGaS Advisors. To learn more about how Trinity is elevating life sciences and driving evidence to action, visit trinitylifesciences.com.
Sign up for the latest intelligence